Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

Oncotarget · 2017 · PMC5593556 · PMID 28915585

Europe PMC DOI

hedged sentence

0.0096

closest p · 0.2× alpha

0.0096

boldest claim

The sentences

a clear trendp= 0.0096actually significant

borderline significantp=0.05actually significant

Abexinostat increases tumor growth delay when used in triple combination in a borderline significant way (p=0.05) with a clear trend to improved survival (logrank test for trend p= 0.0096) (Figure 6F , Supplementary Figure 2E ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.